Last reviewed · How we verify
Vaxzevria
Vaxzevria is a Biologic drug developed by Medical University Innsbruck. It is currently in Phase 3 development.
Vaxzevria is a viral vector vaccine for the prevention of COVID-19, developed by Oxford University and AstraZeneca using the modified chimpanzee adenovirus ChAdOx1 as a vector. It targets the spike glycoprotein of the SARS-CoV-2 virus, classified as a vaccine antigen.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vaxzevria |
|---|---|
| Sponsor | Medical University Innsbruck |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
- Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (PHASE2)
- VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
- Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) (PHASE3)
- COVID-19 Fourth Dose Study in Australia (PHASE3)
- VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
- Adaptive Immune Response to COVID-19 Vaccination
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxzevria CI brief — competitive landscape report
- Vaxzevria updates RSS · CI watch RSS
- Medical University Innsbruck portfolio CI
Frequently asked questions about Vaxzevria
What is Vaxzevria?
Who makes Vaxzevria?
What development phase is Vaxzevria in?
Related
- Manufacturer: Medical University Innsbruck — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing